A Chitosan Derivative Contained Nanostructure Lipid Carriers with Charge-reversal and pH-Sensitive Membranolytic Capability for Lysosomolytic Anti-cancer Drug Delivery
Minjie Sun,Qun Zhao,Ying Xie,Hongzhi Qiao,Zhigui,Sai Li,Qineng Ping
2014-01-01
Abstract:SUMMARY An amphiphilic N-arginine-N-octyl chitosan derivatives (AOCS) modified nanostructure lipid carriers (ANLCs) with charge-reversal and pH-sensitive membranolytic capability was developed for anti-cancer drug delivery. The ANLCs was rich in positve in endo/lysosome acid micro-environment whereas negative at physiological pH. The proton sponge effect of arginine residues destroy endo/lysosome to ensure the lysosomal escape of the anti-cancer drug to reach the target tissue. INTRODUCTION As nano-drug delivery systems (NDDSs) have been widely studied, more and more attentions were paid to their intracellular fate. Amounts of NDDSs internalize cells via endosome-lysosome path, while lysosome, an organelle encapsulates acidic cytoplasm containing many types of enzymes, may induce degradation of NDDSs and its loaded active drugs. Unfortunately nanocarriers without special function lack the ability to escape from endosome–lysosome timely, resulting in poor therapeutic index of the loaded active agents. Therefore, lysosomal escape is fundamental for drugs sensitive to lysosomal degradation or that needs to reach extra lysosomal targets. Many endo/lysosomal escape approaches depending on the weak acidic environment have been reported. Many nanocarriers composed of cationic polymers, such as polyethylenimine (PEI), polylysine, poly(L-amino esters) were designed to endo/lysosome escape drug delivery. PEI was the most efficient agent for lysosomal escaping. However, these cationic polymers caused high cytotoxicity to cells for strong positive charge and nondegradable in vivo. Some modification, such as conjugating branches to these polymers, could reduce the cytotoxicity, while the lysosomolytic capability was decreased. The fusogenic lipid, such as Dioleoylphosphatidylethanolamine (DOPE) was added in liposomes formulation as “helper lipid” to facilitate their endo/lysosomal escape. It has been suggested that under mild acidic environment of endo/lysosome, DOPE might induce fusion between DOPE composed liposome and endo/lysosome membrane, resulting the leakage of entrapped agents to cytoplasm. However, the high cost limited the application of fusogenic lipid. In this study, the ANLCs was composed of a shell of ampholyte, amphiphilic molecule and phospholipid and a core of hydrophobic lipids. The ANLCs could be triggered by tumor tissue pH and undergo a change from negative-charge to positivecharge. Then positive charge increased as it enter endo/loposome and destroy endo/lysosome to ensure the lysosomal escape of the anticancer drug to reach the target tissue. EXPERIMENTAL METHODS NLCs and ANLCs were prepared as previously described by our group with some adjustment [1] . PC, Labrafac CC, Glycerol Trilaurate with or without calcein/ Hydroxycamptothecine(HCPT) were dissolved in methanol/DCM (8:2) and dried then was dispersed in AOCS solution. The suspension was sonicated under 400 W for 15 min, followed by extruding through 0.45m filters to obtain the final NLCs or ANLCs. The particle size and zeta potential in different pH were measured by using Zetaplus (Brookhaven Instruments, UK) at 25 °C. The HCPT loaded in the particles was determined by HPLC method. HepG2 cells were incubated with Calcein-NLCs, Calcein-ANLCs for 1 h. The sample was replaced with RMPI1640 and incubated for another 0 h and 3 h respectively. Lyso-tracker red was added to stain the lysosomes and a confocal laser scanning microscope (CLSM, Olympus FV300-BXCarl Zeiss LSM-410, Tokyo, Japan) was used to exam the cells after incubation. Male Kunming mice were inoculated subcutaneously in the right armpits with 0.1 mL Heps cell suspension (4×10 6 ) to establish tumor-bearing mice. After a week, the mice were weighed and randomly divided into four groups (n = 5). The control saline, HCPT-injection, NLCs and ANLCs were intravenously administered via the tail vein at a dose of 2.5 mg/kg every 2 days for 5 times (Day0, 2, 4, 6, 8, 10). At day 11, all mice were sacrificed and the tumor mass was removed, photographed. RESULTS AND DISCUSSION